Saline Vehicle Increase the Ability of Drug Patch Test in Cutaneous Adverse Drug reactions

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200805005

Enrollment

100

Registered

2020-08-05

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To evaluate the efficacy of drug patch test using 0.9% saline vehicle and comparison with standard vehicles in CADRs. Drug patch test

Interventions

Patch test by suspected drug

Experimental Procedure/Surgery

patch test

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: patients who were diagnosed with delayed type hypersensitivity CADRs. including DRESS, MP rash, FDE, lichenoid drug eruption, exfoliative dermatitis, Eczematous drug eruption, SJS/TEN and AGEPby dermatologists from outpatient and inpatient units of a tertiary referral medical center, Phramongkutklao Hospital

Exclusion criteria

Exclusion criteria: We excluded patients with type 1 hypersensitivity CADRs and patients who currently on immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
positive 48, 96 hours Drug patch test	—

Secondary

Measure	Time frame
safety reading 48, 96 hours patch test	—

Countries

Thailand

Contacts

Public ContactSupitchaya Thaiwat

Phramongkutkloa hospital

thaiwat@pcm.ac.th0629792463

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026